Fusion Antibodies PLC on Wednesday said it is expanding its collaboration agreement with the National Cancer Institute.
Fusion Antibodies is a Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market. Its shares were down 3.8% to 3.27 pence each in London on Wednesday afternoon.
NCI, part of the US National Institutes of Health, is the US federal government’s principal agency for cancer research and training.
Fusion Antibodies said it has agreed an expansion to its collaboration agreement with NCI.
It explained that the expansion will include the humanisation by fusion of several of NCI’s existing camelid nanobodies. These are small antibodies derived from camel species.
Chief Scientific Officer Richard Buick commented: ‘We are excited to deploy our class leading humanisation technology to these nanobodies developed by Mitchell Ho’s group at the NCI, as they have shown excellent activity in published models for CAR-T therapy. We look forward to being able to assist the NCI in their path to clinical success and to continuing to foster goodwill with the NCI in this wider capacity.’
Copyright 2024 Alliance News Ltd. All Rights Reserved.
